Lisi Group (FII) Q1 2025 TU earnings summary

Executive summary

• Sales increased by 8.3% year-over-year to €486.7m in Q1 2025, mainly driven by strong performance in aeronautics.

• LISI AEROSPACE led growth with a 16.6% rise, while LISI MEDICAL grew 12.6% and LISI AUTOMOTIVE declined 5.7%.

Financial highlights

• Consolidated sales reached €486.7m, up 8.3% compared to Q1 2024; adjusted growth was 7.5% after currency and scope effects.

• Positive currency impact of €6.9m (1.4% of sales); perimeter effect of -€3.0m due to scope change.

• EBIT and net profit for 2024 were €56.0m and €37.5m, respectively.

Outlook and guidance

• Group expects a third consecutive year of improvement in key financial indicators, including EBIT and positive Free Cash Flow.

• Cautious outlook due to uncertainties around tariffs, exchange rates, and global economic conditions.

• LISI AEROSPACE benefits from strong order book and production ramp-up; LISI AUTOMOTIVE anticipates continued slowdown; LISI MEDICAL sees promising long-term growth.